MDxHealth (R): Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients

MDxHealth SA (“MDxHealth, or the “Company”), (Euronext: Brussels MDXH.BR), an international healthcare company, developing and offering molecular diagnostic tests to personalize the diagnosis and treatment of urologic cancer, today announced promising research results with a new liquid biopsy test in development. Data from this study, published in The Prostate, January 12, 2018 indicate that the test has the potential to help guide personalized treatment of castration-resistant prostate cancer (CRPC) patients.

Source: https://globenewswire.com/news-release/2018/01/18/1296115/0/en/MDxHealth-R-Develops-Blood-Test-to-Guide-Precision-Treatment-of-Castration-Resistant-Prostate-Cancer-Patients.html